Association of KATP Variants With Coronary Microvascular Dysfunction (CMD) and Refractory Angina Pectoris (RAP) in Coronary Artery Disease (CAD) Patients With Increased Serum Lipoprotein(a) Levels
Authors' conclusion
KATP rs141294036 may serve a potential genetic marker for hyperlipoprotein(a)emia, CMD, and RAP in patients with CAD.
Study context
- Population
- Newly diagnosed patients with CAD
- Participants
- 1,148 participants
- Exposure
- KATP variant genotypes in CAD patients with vs without hyperlipoprotein(a)emia
- Outcome
- Hyperlipoprotein(a)emia risk by KATP variant
Methodological detailsgenetic association study
- Genetic association study
Main finding
As reported in the abstract
Adjusted odds ratio (95% CI)P value
rs2285676 AA + GA genotype
1.44(1.10–1.88)
P = 0.008rs1799858 CC genotype
1.33(1.03–1.73)
P = 0.030rs141294036 CC genotype
1.43(1.10–1.87)
P = 0.008Observational data: associations, not effects.
Further findings
CMD risk
| aOR (95% CI) | P value | ||
|---|---|---|---|
| rs141294036 CC genotype | 1.62 (1.23–2.13) | P = 0.001 | |
| 0.512Adjusted odds ratio (log scale) |
RAP risk · median follow-up 50.6 months
| aHR (95% CI) | P value | ||
|---|---|---|---|
| rs141294036 CC genotype | 2.05 (1.22–3.43) | P = 0.007 | |
| 0.20.5125Adjusted hazard ratio (log scale) |
CMD risk
- Only rs141294036 was associated with increased CMD risk
Exosome-derived microRNAs between rs141294036 genotypes
- Significantly differentially expressed exo-miRs
- 152
- Exo-miRs confirmed in RAP patients with hyperlipoprotein(a)emia and CMD
- 10
Original publication
Association of KATP Variants With CMD and RAP in CAD Patients With Increased Serum Lipoprotein(a) Levels. J Clin Endocrinol Metab. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →